Founded September 2018
Stage Technology development
Investor Trendlines Incubators Israel
CEO Liron Tayeb
Hyblate increases the efficacy of ablation procedures with a proprietary catheter that self-adjusts to the particular anatomy of each patient’s pulmonary veins. Hyblate’s new generation ablation catheter is comprised of 12 independent arms, each fitted with an electrode that carries out the ablation procedure. This allows the catheter to self-adjust to each patient’s unique pulmonary vein anatomy. The design enables easier maneuverability and better contact with the targeted tissue resulting in a faster procedure and a more complete line of ablation.
Additionally, the Hyblate catheter includes a distal tip with a single electrode that can deliver point-by-point focal ablation if required by the physician during the procedure.
Hyblate’s unique AFib catheter provides:
Hyblate’s catheter is designed to work with both RF, the most common ablation energy, and electroporation, an alternative electrical energy source currently being studied in the clinical setting.
Hyblate’s treatment is expected to lead to higher success rates, reduced repeat ablation procedures, and improved patient outcomes in this very large global market.
Formerly, R&D project manager, cardiology, Edwards Lifesciences; BSc, biomedical engineering, Technion-Israel Institute of Technology; MBA, Ariel University (2019)
Senior cardiologist, expert in cardiac electrophysiology, Rambam Health Care Campus; senior clinical lecturer, Technion-Israel Institute of Technology
Director, Cardiology Department, Rambam Health Care Campus; professor, physiology and cardiology, Technion-Israel Institute of Technology
Prior CEO and BD roles across several clinical indications with a successful track record in medical technology companies.
Atrial fibrillation (AFib) is a condition that causes an irregular heart beat (arrhythmia) due to a malfunction in the heart’s electrical system. For people with AFib, the heart’s upper chambers beat irregularly and out of sync with the lower chambers.
According to Circulation Research, AFib is associated with a 5x increased risk of stroke, 3x increased risk of heart failure and 2x increased risk of death.
Medication is the first line of treatment, yet 1 in 2 people are unresponsive to medication. For the 35M people worldwide with persistent AFib, the only alternative is a catheter-based therapy known as pulmonary vein isolation (PVI) that scars the heart tissue and prevents the abnormal electrical signals originating in the four pulmonary veins from traveling to the left upper chamber of the heart. PVI allows the heart’s normal rhythm to return.
The leading PVI technologies use either heat (RF) or cold (cryotherapy) to ablate the heart tissue and isolate the problematic electrical signals.
Ablating with RF heat technology requires painstaking point-by-point ablation around each pulmonary vein. It may give the doctor the ability to ablate any particular tissue, but it takes several hours and often fails to create a full isolation of the pulmonary veins. Ablating with cooling technology requires fixed-sized balloons that more rapidly ablate tissue in a one-shot procedure but cannot fully address the anatomical differences among different patients and their pulmonary veins.
The result: existing AFib ablation solutions are associated with a one-year failure rate of up to 30%; recurrent AFib; and repeat ablation procedures.
